{"DataElement":{"publicId":"2594484","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product Other Agent  Occurrence Therapies Specify","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling._Not otherwise specified._A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._Occurrence; an instance of something happening._the free text field related to therapy.","longName":"AGVHD_PRPRG_OTHR_SPC","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2594442","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product Other Agent  Occurrence","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling._Not otherwise specified._A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro._Occurrence; an instance of something happening.","longName":"AGVHD_PRPRG_OTR_OCR","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2594377","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.:The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill\r\ndiseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not\r\noccur.:A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling.","longName":"C4980:C61155:C42639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Finished Pharmaceutical Product","conceptCode":"C42639","definition":"A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2920B866-F5D4-014B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-10","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"CCURATOR","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2593914","version":"1","preferredName":"Other Pharmacologic Substance Occurrence","preferredDefinition":"Not otherwise specified.:A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.:Occurrence; an instance of something happening.","longName":"C17649:C1909:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28E5EAA4-BB45-6A7B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-07","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-07","modifiedBy":"ONEDATA","dateModified":"2007-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2182571","version":"1","preferredName":"Pharmacologic Substance","preferredDefinition":"A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"PHARMACOLOGIC SUBSTANCE","context":"caCORE","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D727D9B9-FB5E-1E8C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-03","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-03","modifiedBy":"DWARZEL","dateModified":"2004-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2926BD3F-C3A4-5CCE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-04-28","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018810","version":"1","preferredName":"Therapies Specify","preferredDefinition":"the free text field related to therapy.","longName":"TX_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184338","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"Specify","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2084-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BA236E-6B3E-350B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-25","modifiedBy":"CAMPBELB","dateModified":"2008-03-28","changeDescription":"released as entered during ISO compliance update","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_gvhd_pro_oth_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the other agent used","type":"Preferred Question Text","description":"Specify the other agent used after the start of the preparative regimen to prevent acute GVHD or graft rejection","url":null,"context":"NHLBI"},{"name":"CRF Text","type":"Alternate Question Text","description":"Specify","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2594484","type":"BRIDG Mapping Path","description":"MaterialName.name WHERE PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Therapy\" AND PerformedSubstanceAdministration > Pruduct > MaterialName AND PerformedSubstanceAdministration.reasonCode = \"prevent acute GVHD\" OR \"prevent graft rejection\" AND DefinedSubstanceAdministration > DefinedCompositeRelationship > DefinedProcedure.nameCode = \"Perform Preparative Regimen\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"29279ED2-D867-0161-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-10","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"ALEYR","dateModified":"2019-04-13","changeDescription":". .1/8/14mn-added Bridg info.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}